NCT02713776 - Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 13, 2016

Primary Completion Date

January 8, 2021

Study Completion Date

January 8, 2021

Conditions

Enterostomy

Interventions

DRUG

Pasireotide

Pasireotide 0.9 mg by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of pasireotide Long Acting Release (LAR) 60mg on Day 4 morning.

DRUG

Placebo

Placebo by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of placebo on Day 4 morning.

Trial Locations (14)

30029

Chu Caremeau, Nîmes

31059

Toulouse - Chu Purpan, Toulouse

33600

Bordeaux Chu - Hopital Haut-Leveque, Pessac

34298

Institut Regional Du Cancer Val D'Aurelle, Montpellier

38700

Chu Albert Michallon, La Tronche

63003

Chu Estaing, Clermont-Ferrand

69008

Centre Leon Berard, Lyon

69495

Centre Hospitalier Lyon Sud, Pierre-Bénite

75012

Hopital Saint Antoine, Paris

76031

Chu Rouen Ch. Nicolle, Rouen

80054

Chu Amiens-Picardie, Amiens

92110

Hopital Beaujon, Clichy

59 067

Hôpital Claude HURIEZ - CHRU Lille, Lille

13 915

Chu Marseille - Hopital Nord, Marseille

All Listed Sponsors

lead

Hospices Civils de Lyon

OTHER